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nObjectives: To explore an alternative approach to quantifying the bur-
den of side effects at 1 year after treatment for prostate cancer among
both patients and their partners. Methods: We analyzed data from 75
couples in the Family and Cancer Therapy Selection study. Paired
patients and family members were independently asked about their
willingness to pay (WTP) for a hypothetical new treatment that cures
prostate cancer without side effects if they could reconsider their
treatment decision by indicating the maximum amount they would
be willing to pay given 11 separate “bids” ranging from $0 to $1500
per month. Descriptive and regression analyses were conducted for
patients and family members controlling for sociodemographic
characteristics and health status; Spearman correlations were also
examined. Results: Among 75 couples analyzed, the income-adjustedor patients and $650.2 (SE 72.2) for family members. The WTP between O
entio
al So
ttp://dx.doi.org/10.1016/j.jval.2012.03.003atients and family members was correlated (Pearson  0.30; P  0.01).
fter adjusting for covariates, the adjusted mean WTP per month was
588.1 (SE 65.77) for patients and $819.4 (SE 74.33) for family members.
anting to avoid side effects at baseline predicted higher WTP for
atients (P  0.010). Experiencing sexual side effects was predictive of
igher WTP for family members (P  0.047). Conclusions: Fairly high
TP amounts for a hypothetical treatment without side effects sug-
ests that patients and their partners are experiencing important bur-
ens 1 year after treatment. The higher amounts partners are willing to
ay and the correlation with sexual side effects suggest that they are
erceptive of significant treatment burdens.
eywords: family member, patient, prostate cancer, side effect, willing-
ess to pay.ean WTP estimates per month were $400.8 (standard error [SE] $54.3) Copyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Prostate cancer is the most commonly diagnosed cancer, the sec-
ond leading cause of cancer-related deaths among men in the
United States [1], and is an important public health problem in
terms of economic and personal burden [2–5]. Men diagnosed with
clinically localized prostate cancer have a number of treatment
options available to them [6]. All treatment options result in ad-
verse effects (primarily urinary, bowel, and sexual), although the
severity and frequency may vary between treatments. Urinary
dysfunction, especially incontinence, appears to be more common
with radical prostatectomy and bowel dysfunction with external
beam radiation therapy. Sexual dysfunction is common following
all treatments. These side effects result in compromised quality of
life, causing burden for both patients and their family members,
but quantifying the harm associated with sides effects of cancer
therapies perceived to be life-saving is challenging because of cog-
nitive dissonance and adaptation [7].
* Address correspondence to: Chunyu Li, Division of Cancer Prev
uford Highway NE, MS K-55, Atlanta, GA 30341, USA.
E-mail: Cli11@cdc.gov.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.One way to measure the personal benefit of a medical therapy
is to assess an individual’s maximum willingness to pay (WTP) for
the treatment. WTP studies have been widely conducted to eval-
uate patients’ and family members’ preferences for treatment for
cancer and other chronic conditions [8–12]. In settings where in-
dividuals cannot directly purchase the benefit under consider-
ation (e.g., clean air, symptom-free quality of life), assessment of
WTP through surveys and interviews has been argued to be a the-
oretically valid alternative [13,14].
Few studies have estimated patients’ WTP for prostate cancer
treatment [15–17]. These limited WTP studies have been per-
formed among patients with little attention paid to the prefer-
ences of family members. Family members are potentially signif-
icantly affected by the side effects of treatment their loved ones
experience through many mechanisms [18–20]. Thus, including
partners in quantifying the burden of side effects associated with
treatment may be important to fully assessing the total impact of
prostate cancer therapies.
n and Control, Centers for Disease Control and Prevention, 4770
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717V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 1 6 – 7 2 3The purpose of this study was to 1) estimate WTP as a method
of quantifying the burden associated with side effects 1 year after
prostate cancer treatment among patients and their partners; 2)
explore variations in WTP by population characteristics and re-
ported declines in urinary irritation, urinary incontinence, and
sexual function; and 3) examine the concordance of WTP esti-
mates of patients with estimates of their family members. We
hypothesized that patients (and family members) who experience
fewer side effects would report lower WTP and patients experienc-
ng more side effects would report higher WTP amounts.
Methods
Study design
We conducted a retrospective study using data from the Family
And Cancer Therapy Selection study, a 3-wave self-administered
survey (baseline, 6-month follow-up, and 12-month follow-up)
among patients with newly diagnosed prostate cancer in multiple
clinics. Recruitment procedures and patient eligibility were de-
scribed elsewhere [21]. Briefly, newly diagnosed patients were ap-
proached in urology practice sites in California, South Carolina,
and Texas. Interested patients signed consent forms and received
a take-home survey to return by mail. Patients identified a family
member to participate in a separate baseline survey. Mailed fol-
low-up surveys to patients and family members were adminis-
tered at 6 and 12 months to ask about treatment outcomes and
satisfaction with care. WTP questions were asked at 12-month
follow-up only. Study materials were approved by the institutional
review board at each accrual site and the coordinating center. Par-
ticipants received $25 after completing the baseline survey.
A total of 423 patients were approached for participation (Fig.
1). Of these, 240 met eligibility criteria and 198 (83%) returned the
survey prior to initiating treatment. Overall, 240 patients and 193
partners completed the baseline survey. Of these, 131 patients
(89.1% of 147 who completed the 12-month survey) and 84 part-
ners (87.9% of 99 who completed the 12-month survey) responded
to the WTP questions at 12-month follow-up. Seventy-five couples
responded to the WTP questions at 12-month follow-up and were
included in the analysis.
Measures
WTP
On the basis of published survey methods for assessing WTP [8,14],
e used a payment-scale WTP question to determine the maxi-
um amount a patient (or family member) was willing to pay for
hypothetical new treatment that could cure prostate cancer
ithout side effects. Prior to our study, we developed the WTP
uestions and conducted focus groups of prostate cancer survi-
ors to pilot evaluate the items. Changes were made on the basis
f the feedback [21].
The specific question for patients and their family members was as
follows:
Imagine you/your loved one had just been diagnosed with prostate
cancer and had to make your/his treatment decision again. How-
ever, a new drug-based treatment for prostate cancer is now avail-
able that has absolutely no side effects, such as fatigue, pain, incon-
tinence, impotence, or changes in your/your loved one’s ability to
do the things you/he likes to do. This new treatment has the same
chance of cure as the treatment you/he received. Assume for the
moment that insurance would not cover the full costs of this treat-
ment so you and your loved one would have to pay for it. You/your
loved one would need to keep taking this therapy indefinitely. You/
your loved one would not need any other treatment such as surgery
or radiation. For each monthly cost listed below, please indicatehow willing you would be to pay that amount of money out of your
own pocket with the resources you and your loved one currently
have for this new cancer treatment.
The WTP question contained 11 separate “bids”: $25, $50, $75,
$100, $150, $200, $250, $500, $750, $1000, and $1500. Respondents
were asked to respond by checking one of four categories (No,
definitely not; No, probably not; Yes, probably; Yes, definitely) for
each bid. The question was designed to simulate a bidding game
where respondents would be less likely to accept the bid as the
dollar values rose in relation to their monthly income [14]. Provid-
ing “definitely” and “probably” options has been previously dem-
onstrated to reduce pressure on respondents, encourage the bid-
ding game scenario, and yield more accurate estimates than
would a dichotomous choice [22]. If patient/family member an-
swered “Yes, probably” or “Yes, definitely” for a certain amount,
then we defined them as willing to pay for that amount, and we
chose the maximum amount as the final value for their WTP for a
new treatment without any side effect.
Population characteristics
Population characteristics included sociodemographic and health
status assessment. Sociodemographic characteristics were col-
lected for both patients and their family members at baseline,
which included age (60 year, 60–69 year, 70 year), race (white
and nonwhite), education (some college or less vs. college gradu-
ate or higher), annual household income ($40,000, $40,000–
$74,999, $75,000), and whether side effects were important in the
initial treatment decision making (yes/no). In addition, informa-
tion on insurance status (Medicare, non-Medicare private insur-
ance, military insurance, other/unknown), first time diagnosed of
cancer (yes/no), and received surgery (yes/no) was collected for
patients.
Health status assessment (medical characteristics) included
disease classification (moderate/high risk of progression vs. low
risk) [23] and number of comorbidities (0, 1, 2). Patient function
after prostate cancer treatment was measured by the Expanded
Prostate Cancer Index (EPIC) composite score (a well-validated
measure of health-related quality of life among patients with
prostate cancer) [24]. EPIC urinary, bowel, and sexual function
scores ranged from 0 to 100, with 100 reflecting the best possible
health with no symptoms. The EPIC instrument was administered
at baseline prior to treatment and at 12-month follow-up. Changes
in EPIC scores measured decline among prostate cancer patients
accounting for initial function, which is a proxy for severity of side
effects. Changes in scores from the EPIC instrument at baseline
and at 12-month survey were classified as no/mild decline and
moderate/severe decline on the basis of previously established
grouping criteria [25]. Decline in scores ranging from 0.1 to 10
points in urinary irritation were considered mild, and changes
above 10 points were considered moderate/severe. Declines in
scores from 0.1 to 25 points were considered mild for urinary in-
continence and sexual function and above 25 points were consid-
ered moderate/severe [25].
 Patients were asked “how important are these potential side
effects (including problems with urinary and bowel function, sex-
ual function and intimacy, pain, tiredness or fatigue) to your deci-
sion?” If the patient answered “very important” to any of those
potential side effects, then he was identified as considering avoid-
ance of side effects in his treatment decision. Family members
were asked, “Besides curing the cancer, which aspects of treat-
ment are important to you?” If they chose any of these (urinary
and bowel function, sexual function and intimacy, pain, tiredness
or fatigue), they were identified as considering avoidance of side
effects in the treatment decision.
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We used data from the baseline and 12-month follow-up surveys
from 75 couples (patients and their spouse/partner) (Fig. 1). First,
we described population characteristics for patients and family
members. We also used chi-square tests to compare the analyzed
sample with the full study sample at baseline to examine charac-
teristics associated with the probability of responding to WTP
questions (potential self-selection). Second, we presented the ob-
served distribution of WTP among patients and family members in
Figure 2 in the format of cumulative proportion and the observed
mean and median WTP for patients and family members in the
study sample. We then standardized WTP amounts by household
income. Prior studies have demonstrated that income signifi-
cantly affects people’s WTP [8,9,14]; thus, we scaled responders
Fig. 1 – Consort flow diagram for analyzed sample fromwith higher and lower household incomes to the median annualincome observed in the sample. This was accomplished by divid-
ing an individual’s WTP by his annual income (e.g., percentage of
income willing to pay) and multiplying that amount by the median
household income.
We used Spearman’s correlations to examine WTP amounts
between patients and their family members. Generalized linear
models using a gamma distribution and log link were used to ex-
amine the association of patient covariates including age and
change in urinary and sexual function scores. A gamma distribu-
tion with a log link was selected to account for skewness in the
distribution of WTP amounts [26]. Additional covariates included
in the model were patient’s age, patient’s race, insurance, house-
hold income, responder’s education, responder’s rating of impor-
tance for avoiding side effects in the initial treatment decision,
Family and Cancer Therapy Selection (n = 75 couples).theresponder’s count of comorbidities, changes in patient’s EPIC
719V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 1 6 – 7 2 3scores, and site. The model results we present are estimated in-
come-adjusted mean WTP amounts and 95% confidence intervals
for each variable rather than the gamma model’s coefficients to
assist the readers in interpreting relationships between response
levels in the study variables and WTP amounts. These estimated
WTP amounts were calculated by using the margins function in
Stata by setting all other covariates to the mean level. Correlation
in the error term of WTP among patients and family members
from the same household was incorporated into the analyses by
clustering on family ID. We applied bootstrapping to estimate the
standard errors (SEs) with 200 replications to account for the im-
pact of a small sample size. Analyses were conducted by using
Stata version 11.2 [27]. Given a small sample of 75 couples and
potential overfitting, we explored using different model specifica-
tions to examine the robustness of the results and assumptions.
We also did rigorous model selection by using Akaike Information
Criterion (AIC) and Bayesian Information Criterion (BIC) and ex-
amined the impact of outliers.
Sensitivity analysis
To test whether the certainty of response affected the results, we
ran the analysis by using only the highest “Yes, definitely” bid as
the dependent variable (WTP). In addition, we reanalyzed the data
by using a WTP value that was the midpoint between the respon-
dents’ highest accepted bid and the next highest bid. Our using
respondents’ “Yes, probably” bids is somewhat conservative be-
cause WTP will presumably be somewhere in the range between
the highest bid that is accepted and the next highest bid.
Results
Population characteristics
Subjects who responded to the WTP questions were mostly white
and had an education of college graduate or higher compared with
those who did not respond to the WTP questions. No differences in
other characteristics were found between the sample of responders
and the original study sample (data not shown). The sociodemo-
graphic characteristics and health status of 75 couples who met the
inclusion criteria for the analysis are shown in Table 1. Patients were
Fig. 2 – Willingness to pay for prostate cancer treatment
without side effects among patients and their family
members at 1 year after diagnosis. WTP, willingness to
pay.primarily white (83.6%), graduated from college (68.0%), and had anannual household income of more than $75,000 (65.3%). Similarly,
75% of family members were white and 57.3% graduated from col-
lege. The majority of patients (92.0%) and family members (77.3%)
reported that side effects were an important factor in the treatment
decision. Most (78.4%) patients were diagnosed with a cancer for the
first time, and 73.3% of them had one or more comorbidities. Many
patients experienced some urinary or sexual side effects at 1 year
after treatment, 82.4% for sexual function, 93.3% for urinary inconti-
nent function, and 94.7% for urinary irritation function.
Observed and income-adjusted WTP
The WTP values varied from approximately 1% to 60% of respon-
dents’ median annual household income. Maximum WTP values
showed a bimodal distribution, with 63.4% of patients accepting
bids less than $250 and 18.3% accepting the $1500 bid. Among
family members, 39.3% accepted bids less than $250 and 36.9%
accepted the $1500 bid. From the frequency distributions of the
WTP values, we mapped demand curves for this hypothetical
treatment decision for patients and family members. Figure 2 dis-
plays the curve with price (WTP) on the vertical axis, against the
cumulative proportion of the sample willing to pay a sum up to
any given price. The demand curve for family members is higher
than that for patients. Among 75 couples who were included in the
analysis, the observed mean and median WTP per month were
$563.7 (SD $553.2) and $250 for patients and $804.3 (SD 598.5) and
$500 for family members, respectively. Income-adjusted mean
WTP per month was $400.8 (SE 54.3) for patients and $650.2 (SE
72.2) for family members. The unadjusted WTP amounts for pa-
tients and family members in the same household were signifi-
cantly correlated (Pearson 0.30; P  0.01).
Population characteristics and WTP
The income-adjusted WTP per month varied by the sociodemo-
graphic characteristics and medical characteristics (Table 2). No-
tably, patients reported significantly lower WTP amounts ($588; SE
$66) than did their family members ($819; SE $74; P 0.015). White
patients reported higher WTP amounts than did nonwhite pa-
tients. Patients who reported at baseline that side effects were
important in the initial treatment decision (P  0.01) and patients
from California reported higher WTP amounts than did patients
from other study locations. Patients who experienced moderate to
severe declines in urinary and sexual function from baseline to a
12 month follow-up reported slightly higher WTP amounts than
did patients who did not experience functional declines, but the
differences were not statistically significant. Race and the impor-
tance of side effects in the initial decision were not associated with
different WTP amounts among family members. Family members
of patients who reported declines in sexual function did report
higher mean WTP amounts ($714) than did family members of
patients who did not report declines in sexual function ($429), P
0.047. Declines in patient’s urinary function were not associated
with differences in family member’s WTP amounts. Family mem-
bers of patients from Texas reported higher WTP amounts than
did family members of patients from other study locations.
Figure 3 displays the demand curve of both patients and family
members associated with declines in sexual function. The figure
displays WTP amount on the vertical axis against the cumulative
proportion of the sample willing to pay an amount up to any given
price. Separate lines are displayed for patients and family mem-
bers who experienced moderate/severe declines in sexual func-
tion and responders who did not.
Sensitivity analysis
Different model specifications, including log-linear models of WTP
amounts instead of the gamma distribution, provided consistent re-
sults. Using only the “Yes, definitely” response to define the highest
720 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 1 6 – 7 2 3Table 1 – Description of sample characteristics of prostate cancer patients and family member pairs analyzed at 12-mo
follow-up.
Characteristic n (%)
Patients
(n  75)
Family members
(n  74)
Age, y
60 23 30.67 31 41.33
60–69 37 49.33 36 48.00
70 15 20.00 7 9.33
Race
White 61 83.56 54 75.00
Nonwhite 12 16.44 18 25.00
Education
High school or less 5 6.67 8 10.67
Some college 17 22.67 24 32.00
College graduate 26 34.67 30 40.00
Graduate degree 25 33.33 13 17.33
Household income ($ per year)
40,000 9 12.00 9 12.00
40,000–74,999 13 17.33 13 17.33
75,000 49 65.33 49 65.33
Avoidance of side effects in treatment decision
Yes 69 92.00 58 77.33
No 6 8.00 17 22.67
Insurance
Medicare 26 35.62 n/a n/a
Private (non-Medicare) 34 46.58 n/a n/a
VA/military 12 16.44 n/a n/a
Other/unknown 1 1.37 n/a n/a
First-time diagnosis of cancer
Yes 58 78.38 n/a n/a
No 16 21.62 n/a n/a
Surgery received
Yes 60 80.00 n/a n/a
No 15 20.00 n/a n/a
Disease classification
Low risk 39 52.00 n/a n/a
Moderate/high risk 36 48.00 n/a n/a
Number of comorbidities
0 20 26.67 n/a n/a
1 34 45.33 n/a n/a
2 21 28.00 n/a n/a
Change in EPIC domain summary scores (12-mo vs. baseline)
Urinary irritation function
No change/mild decrease 4 5.33 n/a n/a
Moderate/severe decrease 71 94.67 n/a n/a
Urinary incontinent function
No change/mild decrease 5 6.67 n/a n/a
Moderate/severe decrease 70 93.33 n/a n/a
Sexual function
No change/mild decrease 12 17.65 n/a n/a
Moderate/severe decrease 56 82.35 n/a n/a
Survey site
USC 49 65.33 49 65.33
UTHSCSA 12 16.00 12 16.00
MUSC 14 18.67 14 18.67
Note. Couples who did not return the survey or did not answer the WTP question were excluded from 12-mo analysis.
Family members reported their own age, race, education, and marital status. Other characteristics about patient’s health status at baseline (e.g.,
risk classification and number of comorbidities) were compared between family members who responded at baseline and those who responded
to the WTP question at 12-mo follow-up.
EPIC, Expanded Prostate Cancer Index; MUSC, Medical University of South Carolina; n/a, not applicable; USC, University of South Carolina;
UTHSCSA, University of Texas Health Science Center at San Antonio; VA, veterans affairs; WTP, willingness to pay.
721V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 1 6 – 7 2 3amount of WTP resulted in slightly lower WTP amounts. The ob-
served mean WTP among patients was $342.8 per month (SD 425.7),
and the income-adjusted mean WTP was $393.7 per month (SE
179.4). Similarly among family members, WTP results were lower
using “Yes, definitely” amounts with an observed mean WTP of
$638.4 per month (SD 592.6) and income-adjusted mean WTP of
$633.0 per month (SD 77.0). Results are similar using the midpoint
between the respondent’s highest accepted bid and the next highest
bid as the WTP.
Discussion
One year after treatment, prostate cancer patients and their family
Table 2 – Willingness to pay for new prostate cancer treatm
members at 1 year after diagnosis.
Characteristic Pa
($ p
Income-adjust
mean
Total* 400.75
Age, y
60 421.58
60–69 394.67
70 369.48
Race
White 443.79
Nonwhite 239.86
Education
Some college or less 364.73
College graduate and above 421.37
Avoidance of side effects in treatment decision
Yes 417.56
No 197.35
Disease classification
Low risk 457.48
Moderate/high risk 330.41
Comorbidities
No other health problems 475.51
1 other health problem 405.14
2 other health problems 345.18
Surgery received
Yes 409.0
No 367.5
Change in EPIC domain summary scores
(12-mo vs. baseline)
Urinary irritation
No change/mild decrease 258.41
Moderate/severe decrease 416.79
Urinary incontinent
No change/mild decrease 224.64
Moderate/severe decrease 424.89
Sexual function
No change/mild decrease 399.58
Moderate/severe decrease 426.20
Survey site
USC 500.07
UTHSCSA 288.07
MUSC 225.29
EPIC, Expanded Prostate Cancer Index; MUSC, Medical University of S
Texas Health Science Center at San Antonio; WTP, willingness to pay
* Statistically significant at the 1% level.
† Statistically significant at the 5% level.members indicated fairly high WTP amounts for a hypotheticaltreatment without side effects, with a mean WTP of $588 per
month for patients and $819 per month for family members. This
suggests that both patients and family members are experiencing
tangible burdens associated with the treatment they originally se-
lected and would be willing to pay considerable amounts out of
pocket to have a treatment that did not cause the side-effect bur-
dens they are experiencing.
Only a handful of studies have previously attempted to
quantify the burden of prostate cancer treatment by using WTP
methods [15–17]. We highlight that our finding that patients and
family members who indicated avoiding side effects was impor-
tant in the initial decision reported higher WTP amounts at 12
months suggests face validity of the WTP approach. In addition,
without side effects among patients and family
WTP
onth)
Family member WTP
($ per month)
95% Confidence
interval
Income-adjusted
mean
95% Confidence
interval
294.26– 507.23 650.15 508.69–791.62
261.43– 581.73 703.57 469.00–938.14
285.54–503.81 624.64 472.32–776.96
185.35– 553.61 554.56 274.24–834.88
320.14– 567.43* 623.92 463.05–784.78
110.73–368.99 807.72 495.28–1120.17
212.87– 516.60 426.08 270.60–581.57
286.20– 556.54 373.01 229.45–516.57
304.87– 530.24* 688.66 523.19–854.13
23.44–371.26 506.08 291.62–720.54
306.29– 608.67 702.14 497.81–906.47
210.22– 450.61 595.97 419.33–772.62
256.47– 694.54 547.00 327.73–766.26
295.70– 514.57 628.49 487.35–769.63
205.80– 484.57 722.13 499.56–944.70
289.3–528.6 589.1 442.3–735.9
165.0–569.9 836.9 478.6–1195.2
0–519.23 352.37 67.33–637.41
300.54–533.03 668.34 519.30–817.38
26.12–423.16 508.15 135.87–880.43
307.22–542.56 659.95 511.93–807.98
168.15– 631.01 429.60 234.46–624.74†
293.45– 558.94 714.18 542.33–886.03
343.61– 656.53* 517.29 357.21–677.37
134.83–441.30† 982.56 519.88, 1445.24†
107.33– 343.26 585.95 324.91–846.99
Carolina; USC, University of South Carolina; UTHSCSA, University ofent
tient
er m
ed
outh
.although the differences were not statistically significantly dif-
722 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 1 6 – 7 2 3ferent, all patients who reported moderate or severe declines in
urinary and sexual function (and their partners) reported higher
WTP amounts than did patients who did not experience de-
clines in function.
The observation that family members were generally willing
to pay higher amounts than their husbands is quite interesting.
Prior studies have reported that patients’ health states in pros-
tate cancer are associated with lower quality of life among part-
ners [28]. Although husbands’ and wives’ WTP amounts were
strongly correlated, our finding that wives report higher WTP
amounts may suggest that family members are quite sensitive
to the burden their husbands are experiencing. Patients and
their spouses may have differing perceptions, especially the
ones related to the impact of sexual functioning on survivorship
[29,30]. Thus, wives may be placing more value on the burdens
their husbands are experiencing, especially the losses in sexual
function that they may be aware of more than other burdens.
To our knowledge, this is the first study to focus on the burden
from side effects associated with prostate cancer treatment for
both patients and family members in their WTP for treatment.
WTP studies have been widely used to evaluate perceived benefit
from treatment/intervention (e.g., cancer screening, vaccination,
and hypothetical new drug) [8,31,32]. Most have focused on pa-
tient’s WTP and did not include others potentially impacted by
treatment such as a spouse.
There were several limitations with our study. First, the results
estimated in this study may not be representative of those in the
general population with localized prostate cancer because of a
small sample size and because patients and family members were
convenient samples recruited in three study clinics. There may be
nonresponse bias because most of the respondent patients (78.4%)
were diagnosed as having cancer for the first time in their life.
Second, eligibility for the analyzed sample was based on the com-
pletion of the baseline survey and the WTP question in the 12-
month follow-up by both the patient and his family member. Sub-
jects who responded to the WTP questions were more likely to be
white with college graduate or higher education level compared
with the overall population identified for the baseline survey. The
0
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Fig. 3 – Willingness to pay for prostate cancer treatment
without side effects among patients and their family
members by level of sexual side effects at 1 year after
diagnosis. WTP, willingness to pay.WTP item was pretested in a small sample of prostate cancer sur-vivors participating in a prostate cancer support group and may
not have been easily understood by all subjects. Third, WTP is
sensitive to income, and income was measured only in broad cat-
egories in this study. Fourth, there are several known limitations
to WTP assessment derived under hypothetical circumstances.
For example, no information is available on current out-of-pocket
health care or other monthly costs, and so the concept of monthly
out-of-pocket costs may not have been well understood by study
participants. There may be starting-point bias (anchoring bias)
and range bias from the WTP question design that could not be
accounted for using self-administered survey among a small sam-
ple [33]. Zero was included in the list of bids; thus, starting-point
bias is likely to be conservative. It is possible, however, that if we
had included a higher or lower range than $0 to $1500, we may
have obtained different results. We note that the self-adminis-
tered WTP assessment is an established method with practical
appeal because it incorporates indirect and intangible value of
treatment and can be used directly for program evaluation and
has been used successfully in other contexts [14,34].
Conclusions
Local-stage prostate cancer patients and their family members
indicated a fairly high WTP for a hypothetical treatment that cures
disease without side effects, suggesting a high perceived burden
associated with the presence of side effects at 1 year after treat-
ment. Family members are generally willing to pay higher
amounts than patients, further highlighting the burden of this
disease and its associated side effects on caregivers. Patients who
experienced more side-effect burden expressed higher WTP
amounts. WTP may be an alternative approach to assessing the
burden of prostate cancer treatment to quality-of-life or utility
measures.
This study estimated the value of avoiding side effects from
prostate cancer treatment and offers an alternative to utility mea-
sures and provides valuable information for patients, family
members, providers, and policymakers in considering the burden
of prostate cancer. Our findings suggest that to fully assess the
harms and benefit of prostate cancer treatments for a society, it is
necessary to include both the patient and affected family member
perspectives.
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study are those of the authors and do not necessarily represent the
official position of the Centers for Disease Control and Prevention.
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